LONDON and MUNICH and NEW DELHI, Jan. 21, 2025 /PRNewswire/ -- Datar Cancer Genetics (DCG) today announced the launch of Target-MRD, an advanced molecular residual disease (MRD) monitoring blood ...

Datar Cancer Genetics (DCG) has launched the Target-MRD blood test, designed for the identification and monitoring of molecular residual disease (MRD) in individuals with solid organ cancers.

London [UK]/ Munich [Germany]/ New Delhi [India], January 22: Datar Cancer Genetics (DCG) today announced the launch of Target-MRD, an advanced molecular residual disease (MRD) monitoring blood ...

Thus, it is important that every Government resists the temptation to ignore these conventions for short-term gains or to settle political scores. Arvind P. Datar is a Senior Advocate.

Unite.AI is committed to rigorous editorial standards. We may receive compensation when you click on links to products we review. Please view our affiliate disclosure. In the digital age, AI-powered ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

$ 0.001 USD 0.00 0.00% ...

Please register yourself for unlimited free access. Redirecting to register page ...